Market Place
Sourcing Support
Faron Pharmaceuticals: Half-Year Financial Results Jan-Jun 2025
12 Sep 2025 //
ACCESSWIRE
Faron Pharmaceuticals Ltd Reports Half-Year Financial Results
27 Aug 2025 //
PHARMAWEB
Faron Pharmaceuticals Announces Half-Year Financial Results
19 Aug 2025 //
ACCESSWIRE
Faron Gets New US Patent for Bexmarilimab in Cancer Treatment
08 Aug 2025 //
ACCESSWIRE
Faron Pharmaceuticals Ltd: Company Holdings
08 Aug 2025 //
ACCESSWIRE
Faron to Present Updated Bexmab Data to Fda, Showing 43%
06 Aug 2025 //
ACCESSWIRE
Faron`s Bexmarilimab Studies Accepted for Oral Presentation
09 Jul 2025 //
ACCESSWIRE
Faron Study Highlights sClever-1 as Immune Blocker in Cancer
03 Jul 2025 //
INDPHARMAPOST
Faron Pharmaceuticals Ltd: Director Dealing
02 Jul 2025 //
ACCESSWIRE
Faron Pharmaceuticals updates Phase II data at EHA 2025
12 Jun 2025 //
ACCESSWIRE
Faron Pharmaceuticals Ltd: Director Donates Shares to Foundation
05 Jun 2025 //
PHARMAWEB
Faron Pharmaceuticals: Director Donates Shares to Foundation
05 Jun 2025 //
ACCESSWIRE
Faron Pharmaceuticals Presents Phase II Data at ASCO 2025
02 Jun 2025 //
ACCESSWIRE
Faron Publishes Phase I BEXMAB Study Data in Lancet Haematology
30 May 2025 //
ACCESSWIRE
Faron`s Bexmarilimab Shows Potential in Myeloid Malignancies
27 May 2025 //
ACCESSWIRE
Faron Reveals New Data on Bexmarilimab for Cancer Patients
23 May 2025 //
ACCESSWIRE
Faron Appoints Ralph Hughes as Chief Business Officer (CBO)
21 May 2025 //
ACCESSWIRE
Faron Accepts Bexmarilimab Data for EHA 2025 Congress
15 May 2025 //
ACCESSWIRE
Faron Pharmaceuticals Ltd: Grant of Options
14 May 2025 //
ACCESSWIRE
Faron Pharmaceuticals Presents Promising BEXMAB Study Data at MDS
12 May 2025 //
ACCESSWIRE
Faron`s Acceptance of Bexmarilimab Ph II Data for ASCO 2025
24 Apr 2025 //
ACCESSWIRE
Holding in Company
17 Apr 2025 //
ACCESSWIRE
Faron Reports Positive Phase 2 Results in Myelodysplastic Syndrome
15 Apr 2025 //
ACCESSWIRE
Faron to Present Bexmarilimab Data at 2025 MDS Foundation Congress
27 Mar 2025 //
ACCESSWIRE
Results of the Annual General Meeting, Change of Directors
21 Mar 2025 //
ACCESSWIRE
Board Changes
21 Mar 2025 //
ACCESSWIRE
Elizabeth, CEO of Kinder Ready, Guides Private School Application
21 Mar 2025 //
ACCESSWIRE
Shareholders` Board Updates Proposal On Member Elections
20 Mar 2025 //
ACCESSWIRE
Faron presents Bexmab data at ASH Annual Meeting
10 Dec 2024 //
PR NEWSWIRE
Faron`s bexmarilimab Developers Named European Inventor Award Finalists
16 May 2024 //
GLOBENEWSWIRE
Faron Confirms Plans for the Coming Months Under New Leadership
16 Apr 2024 //
GLOBENEWSWIRE
Inside Information: Additional Positive Data from the Ph1 Part of BEXMAB Study
18 Mar 2024 //
GLOBENEWSWIRE
Positive Data from the Ph1 Part of the BEXMAB Study Failed
18 Mar 2024 //
GLOBENEWSWIRE
Faron to Host Webcast to Discuss data from Phase 1 of Study of Bexmarilimab
14 Mar 2024 //
GLOBENEWSWIRE
Faron™s Financial Statement Release January 1 to December 31, 2023
13 Mar 2024 //
GLOBENEWSWIRE
Detailed Analysis of BEXMAB Data Provides Insights into Patient Profiles of Responding HMA-Failed MDS Population
25 Jan 2024 //
GLOBENEWSWIRE
Faron Announces First HMA-failed MDS Patient Dosed with Bexmarilimab
09 Jan 2024 //
GLOBENEWSWIRE
Faron Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 //
GLOBENEWSWIRE
Faron Presents Phase 1 Data from BEXMAB in Myeloid Malignancies Trial
11 Dec 2023 //
GLOBENEWSWIRE
Faron Announces Publication of Full Analysis from Phase 1/2 of Bexmarilimab
07 Dec 2023 //
GLOBENEWSWIRE
Faron Initiates Phase 2 Part of BEXMAB Study of Bexmarilimab in HMA-failed MDS
06 Nov 2023 //
GLOBENEWSWIRE
Faron to Present Phase 1/2 Data From BEXMAB Study of Bexmarilimab
02 Nov 2023 //
GLOBENEWSWIRE
Announcement of the Results of Placing, the Issue Price with the Trade Register
27 Oct 2023 //
GLOBENEWSWIRE
Faron Announces Positive BEXMAB Study Update in Relapsed/Refractory AML
11 Oct 2023 //
GLOBENEWSWIRE
Faron to Host Webcast to Discuss Data From Phase I/II Study of Bexmarilimab
02 Oct 2023 //
GLOBENEWSWIRE
Faron Pharmaceuticals Announces Board Changes
22 Sep 2023 //
GLOBENEWSWIRE
Faron Appoints Dr. Birge Berns, MD as Interim Chief Medical Officer
21 Sep 2023 //
GLOBENEWSWIRE
Faron to Present at the H.C. Wainwright 25th Annual Global Investment Conference
06 Sep 2023 //
GLOBENEWSWIRE
Faron Receives FDA Orphan Drug Designation for Bexmarilimab in AML
29 Aug 2023 //
GLOBENEWSWIRE
Faron Reports Half-Year Financial Results, January 1 June 30, 2023
29 Aug 2023 //
GLOBENEWSWIRE
Faron Pharmaceuticals Notice of Half-Year Financial Results
04 Aug 2023 //
GLOBENEWSWIRE
Faron to Participate in Fireside Chat at the Canaccord Genuity Annual Conference
02 Aug 2023 //
GLOBENEWSWIRE
Faron to Hold Conference to Discuss Data from Phase I/II Study of Bexmarilimab
19 Jul 2023 //
GLOBENEWSWIRE
Faron`s latest snapshot suggests antibody has leukemia potential
19 Jul 2023 //
FIERCE BIOTECH
New biomarker data from BEXMAB study at EHA2023
09 Jun 2023 //
PR NEWSWIRE
Faron Appoints Maija Hollmén as CSO
01 Dec 2022 //
CISION
Faron Names Dr. Maija Hollmén as Chief Scientific Officer
01 Dec 2022 //
CONTRACTPHARMA
Faron Pharmaceuticals hails potential of cancer immunotherapy
19 Sep 2022 //
PROACTIVEINVESTORS
Presentation of Biomarker Analysis at ASCO
30 May 2022 //
PRNEWSWIRE
Faron Announces FDA and FMA Approval to Initiate PI/II Bexmarilimab
16 May 2022 //
PRNEWSWIRE
